Want to see AU:HCT full AI Analyst Report?
Top Page
Holista Colltech Limited
(Sydney:HCT)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.06
▼(-28.89% Downside)
Action:Reiterated
Date:08/08/26
The score is primarily held down by weak financial performance (declining revenue, deteriorating profitability, and worsening negative free cash flow), which increases funding and execution risk. Technical indicators also lean bearish with the price below key moving averages and a negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Vertical integration from R&D to distribution
A full-stack model (R&D through manufacturing and distribution) gives lasting control over product quality, cost structure and time-to-market. This reduces reliance on third parties, supports reproducible margins and product differentiation, aiding durable commercialization prospects.
Negative Factors
Persistent negative operating and free cash flow
Chronic cash burn weakens financial flexibility and forces reliance on external funding. Persistent negative operating and free cash flow raise the probability of dilutive equity raises or expensive debt, constraining investment in R&D, manufacturing scale-up and commercial execution over months ahead.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertical integration from R&D to distribution
A full-stack model (R&D through manufacturing and distribution) gives lasting control over product quality, cost structure and time-to-market. This reduces reliance on third parties, supports reproducible margins and product differentiation, aiding durable commercialization prospects.
Read all positive factors
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$17.66M
Dividend YieldN/A
Average Volume (3M)72.05K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth2.96%
EPS Growth-866.67%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding367,834,350
10 Day Avg. Volume123,924
30 Day Avg. Volume72,050
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)28.04
Price to Sales (P/S)5.45
P/FCF Ratio-20.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Holista Colltech Limited Business Overview & Revenue Model
Company Description
Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food...
How the Company Makes Money
null...
Holista Colltech Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.76M | 5.60M | 5.95M | 8.24M | 8.02M |
| Gross Profit | 770.25K | 87.03K | 370.06K | 4.24M | 1.31M |
| EBITDA | -788.46K | 304.37K | -4.52M | -1.02M | -957.40K |
| Net Income | -948.92K | -84.21K | -4.81M | -1.45M | -1.26M |
Balance Sheet | |||||
| Total Assets | 5.87M | 3.34M | 3.35M | 5.52M | 6.93M |
| Cash, Cash Equivalents and Short-Term Investments | 2.16M | 21.72K | 59.77K | 117.53K | 1.21M |
| Total Debt | 1.59M | 1.77M | 1.57M | 1.22M | 890.32K |
| Total Liabilities | 6.29M | 6.71M | 6.74M | 3.96M | 3.95M |
| Stockholders Equity | 1.12M | -1.73M | -1.97M | 2.83M | 4.10M |
Cash Flow | |||||
| Free Cash Flow | -1.52M | -1.02M | -411.67K | -1.19M | -1.72M |
| Operating Cash Flow | -1.35M | -1.01M | -407.12K | -1.11M | -1.68M |
| Investing Cash Flow | -176.36K | 692.12K | -46.70K | -105.69K | 50.35K |
| Financing Cash Flow | 3.65M | 143.75K | 418.42K | 120.85K | 109.49K |
Holista Colltech Limited Technical Analysis
Negative
0.09
Price Trends
0.07
Negative
0.07
Negative
0.07
Negative
Market Momentum
>-0.01
Positive
19.92
Positive
5.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 19.92 is Positive, neither overbought nor oversold. The STOCH value of 5.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HCT.
Holista Colltech Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | AU$215.36M | 23.09 | 56.29% | ― | 174.51% | 265.77% | |
75 Outperform | AU$158.65M | 17.86 | 12.22% | 2.27% | 27.60% | 96.31% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | AU$84.05M | 22.38 | 8.70% | ― | 23.29% | ― | |
45 Neutral | AU$33.25M | -0.36 | 19.78% | ― | 6.22% | 39.68% | |
42 Neutral | AU$17.66M | -18.46 | -321.20% | ― | 2.96% | -866.67% | |
39 Underperform | AU$6.66M | -0.01 | 226.76% | ― | -32.83% | 83.37% |
* Consumer Defensive Sector Average
AU:HCT
Holista Colltech Limited
0.05
-0.05
-52.00%
AU:NOU
Noumi Limited
0.12
-0.07
-36.84%
AU:BLS
Bioxyne Limited
0.94
0.41
77.36%
AU:BUB
Bubs Australia Ltd.
0.09
-0.08
-44.71%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-4.76%
AU:CLV
Clover Corporation Limited
0.95
0.40
73.99%
Holista Colltech Limited Corporate Events
Holista Colltech absorbs ProImmune settlement as cash management tightens
Jul 29, 2026
Holista Colltech reported quarterly group revenue of about $1.50 million, a slight 0.8% increase, with customer receipts rising 12.9% to approximately $1.48 million on better collections, debt recoveries and new deposits. The company’s opera...
Holista Colltech Plans New Share Placement on ASX
Jul 9, 2026
Holista Colltech Limited has notified the ASX of a proposed issue of up to 5,296,055 ordinary fully paid shares, to be undertaken as a placement or other type of equity issue. The securities are intended to be quoted on the ASX, with the company c...
Holista Colltech Secures Convertible Loan to Settle ProImmune Liability
Jul 9, 2026
Holista Colltech Limited, a Perth-based health and wellness company listed on the ASX, develops and markets dietary supplements, low-GI food ingredients, ovine collagen products, and natural sanitizers for consumer and industrial use. Its business...
Holista JV Buys Collie Industrial Site for New Collagen Plant
Jun 18, 2026
Holista Colltech’s joint venture Ovicoll Pty Ltd has acquired a 3,974-square-metre industrial block in Collie, Western Australia, for $231,000 to house a new sheep collagen and nano-collagen production facility. The land purchase follows the...
Holista clarifies JV terms and guarantee for Collie collagen plant
Jun 17, 2026
Holista Colltech has clarified details of its binding joint venture with Hong Kong–listed Swang Chai Chuan to fund, develop and operate an ovine nano-collagen production facility in Collie, Western Australia, including the status of related ...
Holista Colltech shareholders back all resolutions at 2026 AGM
May 25, 2026
Holista Colltech Limited reported that all resolutions put to shareholders at its 25 May 2026 Annual General Meeting were passed by poll. Investors overwhelmingly backed the remuneration report, the elections of directors Robert Gemelli and Sam Ye...
Holista Colltech Signals Governance-Led Turnaround at 2026 AGM
May 25, 2026
Holista Colltech Limited outlined a broad transformation program at its 2026 annual general meeting, highlighting a refreshed board, stronger governance and the substantial resolution of major legacy legal matters. The company reported a stabilise...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.